{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu L"],"funding":["Key Project of the Chinese National Program for Fundamental Research and Development","Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","National Natural Scientific Foundation","Xiehe Scholar Fund"],"pagination":["e3405"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5490461"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5"],"pubmed_abstract":["<h4>Aim</h4>To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes.<h4>Methods</h4>We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model.<h4>Results</h4>Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), -0.33 ml/min per 1.73 m<sup>2</sup>, 95% CI [-0.90 to 0.23]) or"],"journal":["PeerJ"],"pubmed_title":["Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis."],"pmcid":["PMC5490461"],"funding_grant_id":["2016-I2M-2-004","81470937","2012CB517803","81170674"],"pubmed_authors":["Xu L","Li Y","Lang J","Chen L","Xia P","Zhao X","Wang L","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.","description":"<h4>Aim</h4>To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes.<h4>Methods</h4>We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model.<h4>Results</h4>Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), -0.33 ml/min per 1.73 m<sup>2</sup>, 95% CI [-0.90 to 0.23]) or","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2026-04-15T17:09:00.902Z","creation":"2019-03-27T02:48:52Z"},"accession":"S-EPMC5490461","cross_references":{"pubmed":["28663934"],"doi":["10.7717/peerj.3405"]}}